The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
RU486 (MIFEPRISTONE): Mechanisms of Action and Clinical Uses
Abstract
▪ Abstract RU486 (mifepristone) has proved to be a remarkably active antiprogesterone and antiglucocorticosteroid agent in human beings. The mechanism of action involves the intracellular receptors of the antagonized hormones (progesterone and glucocorticosteroids). At the molecular level, the most important features are high binding affinity to the receptor, interaction of the phenylaminodimethyl group in the 11β-position with a specific region of the receptor binding pocket, and RU486-induced transconformation differences in the ligand-binding domain. These particularities have consequences at different steps of the receptor function as compared with agonists. However, the reasoning cannot be limited to the RU486-receptor interaction, and, for instance, there is the possibility of a switch from antagonistic property to agonist activity, depending on the intervention of other signaling pathways. It would be desirable to have derivatives with only one of the two antagonistic properties (antiprogestin, antiglucocorticosteroid) in spite of similarities between steroid structures, receptors involved, and responsive machineries in target cells. Clinically, the RU486-plus-prostaglandin method is ready to be used on a large scale and is close to being as convenient and safe as any medical method of abortion may be. The early use of RU486 as a contragestive as soon as a woman fears a pregnancy she does not want will help to defuse the abortion issue. Research should now be conducted to define an efficient and convenient contraceptive method with RU486 or other antiprogestins. The usefulness of RU486 for obstetric indications, including facilitation of difficult delivery, has to be assessed rapidly. Gynecologic trials, particularly in leiomyomata, should also be systematically continued. The very preliminary results obtained with tumors, including breast cancers, indicate that further studies are necessary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Steroid and Thyroid Hormone Receptor Superfamily
Evans, R. M. (1988) · Science · doi:10.1126/science.3283939 · Cited by 7,439
MOLECULAR MECHANISMS OF ACTION OF STEROID/THYROID RECEPTOR SUPERFAMILY MEMBERS
Tsai, M.-J., & O'Malley, B. W. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.002315 · Cited by 2,932
Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α
Bourguet, W., Ruff, M., Chambon, P., Gronemeyer, H., & Moras, D. (1995) · Nature · doi:10.1038/375377a0 · Cited by 1,177
Steroid Receptor Family: Structure and Functions
CARSON-JURICA, M. A., SCHRADER, W. T., & O'MALLEY, B. W. (1990) · Endocrine Reviews · doi:10.1210/edrv-11-2-201 · Cited by 811
Vegeto, E., Shahbaz, M. M., Wen, D. X., Goldman, M. E., O'Malley, B. W., & McDonnell, D. P. (1993) · Molecular Endocrinology · doi:10.1210/mend.7.10.8264658 · Cited by 760
Contragestion and Other Clinical Applications of RU 486, an Antiprogesterone at the Receptor
Baulieu, E.-E. (1989) · Science · doi:10.1126/science.2781282 · Cited by 483
Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone
Grunberg, S. M., Weiss, M. H., Spitz, I. M., Ahmadi, J., Sadun, A., Russell, C. A., Lucci, L., & Stevenson, L. L. (1991) · Journal of Neurosurgery · doi:10.3171/jns.1991.74.6.0861 · Cited by 379
TRANSCRIPTION ACTIVATION BY ESTROGEN AND PROGESTERONE RECEPTORS
Gronemeyer, H. (1991) · Annual Review of Genetics · doi:10.1146/annurev.ge.25.120191.000513 · Cited by 378
Vegeto, E., Allan, G. F., Schrader, W. T., Tsai, M.-J., McDonnell, D. P., & O'Malley, B. W. (1992) · Cell · doi:10.1016/0092-8674(92)90234-4 · Cited by 377
Allan, G. F., Leng, X., Tsai, S. Y., Weigel, N. L., Edwards, D. P., Tsai, M. J., & O'Malley, B. W. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41805-4 · Cited by 355
Cited by
An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway
Kliewer, S. A., Moore, J. T., Wade, L., Staudinger, J. L., Watson, M. A., Jones, S. A., McKee, D. D., Oliver, B. B., Willson, T. M., Zetterström, R. H., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)80900-9 · Cited by 1,539
Drugs of Abuse and Stress Trigger a Common Synaptic Adaptation in Dopamine Neurons
Saal, D., Dong, Y., Bonci, A., & Malenka, R. C. (2003) · Neuron · doi:10.1016/s0896-6273(03)00021-7 · Cited by 1,147
Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer
Kim, J. J., Kurita, T., & Bulun, S. E. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1043 · Cited by 520
Central serous chorioretinopathy: Towards an evidence-based treatment guideline
van Rijssen, T. J., van Dijk, E. H. C., Yzer, S., Ohno-Matsui, K., Keunen, J. E. E., Schlingemann, R. O., Sivaprasad, S., Querques, G., Downes, S. M., Fauser, S., et al. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.07.003 · Cited by 478
The Treatment of Cushing's Disease
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 465
Metadata
- Authors
- Cadepond, P., Ulmann, M., & Baulieu, M.
- Venue
- Annual Review of Medicine
- Publisher
- Annual Reviews
- Published
- 1997-02
- Volume
- 48
- Issue
- 1
- Pages
- 129-156
- ISSN
- 0066-4219 (ISSN-L)
- 1545-326X
- OpenAlex
- W2167223040
- Cited by
- 424
- References
- 110
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RU486 (MIFEPRISTONE): Mechanisms of Action and Clinical Uses. https://app.cochat.ai/papers/10.1146/annurev.med.48.1.129
- The paper
- Cadepond, P., Ulmann, M., & Baulieu, M. (1997). RU486 (MIFEPRISTONE): Mechanisms of Action and Clinical Uses. Annual Review of Medicine. https://doi.org/10.1146/annurev.med.48.1.129
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.